Establishment and validation of a time-resolved fluoroimmunoassay for transient receptor potential channel 5

doi:10.3969/j.issn.1673-8640.2018.05.017

Abstract

Abstract:

Objective Transient receptor potential channel 5（TRPC5） can be as a marker of breast cancer drug resistance. To establish a method for the diagnosis of breast cancer in vitro drug resistance. Methods Time-resolved fluoroimmunoassay（TRFIA）was established for TRPC5. Anti-TRPC5 antibody was prepared by immunizing New Zealand white rabbits with TRPC5-keyhole limpet hemocyanin （KLH） as an immunogen. Mucin 1 （MUC1） antibody coated immunomagnetic beads to process samples. TRPC5 peptides, coated with 96-well plates as solid-phase antigens, competed with free TRPC5 antigen. Eu³⁺-goat anti-rabbit antibody was used as a tracer. Results The sensitivity was 1 ng/mL for TRPC5 TRFIA. The range was 5-500 ng/mL. The coefficient of variation（CV）was 5.5%. The mean recovery rate was 94.6%. The ED80,ED50 and ED20 of TRFIA were（4.68±0.13）,（321.66±2.77） and （714.42±4.07）ng/mL,respectively. There was statistical significance for the results of chemotherapy-resistant patients and chemotherapy-tolerant patients（P<0.000 1）. Conclusions TRPC5 TRFIA has a certain degree of differentiation between breast cancer chemotherapy resistance or not. It has clinical significance and is worth further study.

Key words: Transient receptor potential channel 5, Time-resolved fluoroimmunoassay, Breast cancer, Chemotherapy resistance

CLC Number:

R446.61

LU Yangfan, HUANG Biao, MA Xin. Establishment and validation of a time-resolved fluoroimmunoassay for transient receptor potential channel 5[J]. Laboratory Medicine, 2018, 33(5): 447-451.

Figures/Tables 8

References 11

[1]	MARINA M, SAAVEDRA H I.Nek2 and Plk4: prognostic markers, drivers of breast tumorigenesis and drug resistance[J]. Front Biosci (Landmark Ed), 2014, 19:352-365.
[2]	MONTELL C. The TRP superfamily of cation channels.[J]. Sci STKE, 2005, 2005(272):re3.
[3]	MA X, CAI Y, HE D, et al.Transient receptor potential channel TRPC5 is essential for P-glycoprotein induction in drug-resistant cancer cells[J]. Proc Natl Acad Sci U S A, 2012, 109(40):16282-16287.
[4]	MA X, CHEN Z, HUA D, et al.Essential role for TrpC5-containing extracellular vesicles in breast cancer with chemotherapeutic resistance[J]. Proc Natl Acad Sci U S A, 2014, 111(17):6389-6394.
[5]	马鑫, 金坚, 汪淋军,等. EVs-TRPC5在检测乳腺癌耐药程度中的应用: CN 103954770 A[P].2014-07-30.
[6]	HANASH S M, PITTERI S J, FACA V M.Mining the plasma proteome for cancer biomarkers[J]. Nature, 2008, 452(7187):571-579.
[7]	杨文蔚, 王志恒, 岳朝艳. 乳腺癌患者血清 CA153、CEA、铁蛋白和降钙素水平的变化及临床意义[J]. 检验医学,2017,32(4):308-310.
[8]	周龙, 雷建平, 李瑶. 粘蛋白(MUC1)与肿瘤的关系[J]. 江西医药, 2008,43(4):364-367.
[9]	张璇, 鲜瑶. 免疫磁珠技术及其在食品微生物检测中的应用[J]. 农产品质量与安全, 2011,1:40-43.
[10]	盛跃颖,陈洪友,张曦,等. 免疫磁珠捕获法检测志贺菌的模拟研究[J]. 检验医学, 2012, 27(3):167-170.
[11]	朱岚,黄飚,张珏,等. 甲状腺球蛋白抗体竞争TRFIA技术的建立及临床应用[J]. 检验医学, 2013, 28(4):305-307.

组别	1	2	3	4	5	6	x	CV（%）
1	1 047 562	1 028 169	1 121 664	1 135 837	1 056 903	1 005 637	1 065 962	4.9
2	1 163 358	1 151 077	1 177 126	1 120 490	1 124 884	1 240 175	1 162 851	3.8
3	1 121 710	1 106 639	1 105 110	1 072 046	1 058 466	1 147 603	1 101 929	3.0
4	1 084 164	1 182 513	1 183 555	1 203 036	1 183 232	1 214 754	1 175 209	4.1
x				1 126 488
CV（%）				5.5

组别	1	2	3	4	5	6	x	CV（%）
1	1 047 562	1 028 169	1 121 664	1 135 837	1 056 903	1 005 637	1 065 962	4.9
2	1 163 358	1 151 077	1 177 126	1 120 490	1 124 884	1 240 175	1 162 851	3.8
3	1 121 710	1 106 639	1 105 110	1 072 046	1 058 466	1 147 603	1 101 929	3.0
4	1 084 164	1 182 513	1 183 555	1 203 036	1 183 232	1 214 754	1 175 209	4.1
x				1 126 488
CV（%）				5.5

样本	TRPC5 添加量（ng/mL）	TRPC5 TRFIA测量值（ng/mL）	TRPC5 TRFIA测定回收率（%）
1	10	11.01	110.12
2	50	47.28	94.57
3	100	85.51	85.51
4	500	466.48	93.30
5	800	716.57	89.57

样本	TRPC5 添加量（ng/mL）	TRPC5 TRFIA测量值（ng/mL）	TRPC5 TRFIA测定回收率（%）
1	10	11.01	110.12
2	50	47.28	94.57
3	100	85.51	85.51
4	500	466.48	93.30
5	800	716.57	89.57

[1]	WANG Rong, XING Lianxiang, HUANG Keliang, LI Xin. MiR-374 promoting proliferation and invasion of breast cancer cells by targeting and down-regulating TRIM35 [J]. Laboratory Medicine, 2023, 38(9): 812-817.
[2]	CHEN Chen, DUAN Qi, LU Jiatuan, ZHAI Xiaojian, WANG Zheng, ZHANG Hao, GUO Man. Expressions of ASH2L and HOXA2 in triple-negative breast cancer patients and their relationship with lymph node metastasis [J]. Laboratory Medicine, 2023, 38(6): 574-578.
[3]	ZHANG Guoliang, LIU Yiwen, HE Yiqing, XU Jing, YANG Cuixia, GAO Feng, LIU Hua. Changes of serum HAS2 and CD44 levels in breast cancer patients and their clinical significance [J]. Laboratory Medicine, 2023, 38(5): 424-429.
[4]	LI Mu, GONG Dongliang, XU Liming, PENG Rong. Relationship of XPC rs2228000 polymorphisms and breast cancer [J]. Laboratory Medicine, 2023, 38(3): 235-239.
[5]	LIU Chong, ZHANG Jing, LI Sheng, ZHAO Qi. Expressions and correlation of miR-335 and Fra-1 in breast cancer [J]. Laboratory Medicine, 2023, 38(2): 143-147.
[6]	GAO Jianchao, WANG Sisi, ZHANG Zhisheng, ZHANG Jingli, LI Xiaoxia, MA Ke, FENG Zhilin, ZHOU Haifeng, WANG Zhanhai. Efficacy and prognosis evaluation of neo-adjuvant chemotherapy for breast cancer based on miR-206，miR-125 and miR-21 [J]. Laboratory Medicine, 2023, 38(11): 1062-1068.
[7]	WANG Xiaoye, DONG Guoyou, LIU Zhiying. Relations of ZEB2 and E-Cad expressions in breast cancer tissues with prognosis [J]. Laboratory Medicine, 2022, 37(9): 815-820.
[8]	YU Fangfang, ZHAO Qi, YANG Liping, WANG Chenyu. Correlation of hematological indexes and expression of HER-2 in patients with breast cancer [J]. Laboratory Medicine, 2022, 37(6): 514-517.
[9]	YE Jingwen, SHEN Yunyue, LIU Yiwen, HE Yiqing, DU Yan, ZHANG Guoliang, GAO Feng, YANG Cuixia. Role of MAPK/ERK signaling pathway in reversing endocrine resistance of breast cancer [J]. Laboratory Medicine, 2022, 37(4): 342-348.
[10]	ZHANG Xinyue, CHEN Liang, ZHENG Yu. Correlation between serum C peptide and insulin-like growth factor binding protein 3 and the risk of breast cancer patient death [J]. Laboratory Medicine, 2022, 37(1): 36-40.
[11]	LIN Jiafei, CHEN Xiaosong, WU Beiying, CAI Gang, LIN Lin. 21-Gene recurrence score in mucinous breast cancer [J]. Laboratory Medicine, 2021, 36(7): 714-718.
[12]	YUAN Muge, WU Wenjian, HU Zhaohui, CHEN Jiachang, YU Shihui, OU Xiaohua, MAO Linlin, WU Haiyan. Germline mutation detection in early-stage breast cancer by next-generation sequencing [J]. Laboratory Medicine, 2021, 36(3): 325-329.
[13]	LIU Xiufen, AO Hongfeng, AO Jinping. Expression of programmed cell death 5 in breast cancer and its clinical value [J]. Laboratory Medicine, 2021, 36(11): 1151-1158.
[14]	HANG Chen, HUANG Biao, PENG Haixia, WEI Xin, XU Weihong, SHENG Huiming, LI Ningli. Role of TRFIA for detecting pepsinogen in screening ulcer gastric cancer [J]. Laboratory Medicine, 2020, 35(7): 721-725.
[15]	JIN Shu, ZHU Qi, ZHU Yuan, YUAN Ya, CAI Xiaoyao, ZHANG Ji, YAN Peiyi. Methylation level and mRNA expression of CpG island of HER2 gene in breast cancer and its adjacent tissues [J]. Laboratory Medicine, 2020, 35(5): 481-486.